Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Every purchase requires a research-use affirmation at checkout
Holman RR, Bethel MA, Mentz RJ, EXSCEL Study Group, et al
Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial
Yes, some users may experience mild effects, such as temporary hypoglycemia, water retention, or muscle tightness, due to enhanced cell hydration
Eli Lilly reported these results in mid-2025, and the retatrutide availability timeline now points toward potential FDA approval no earlier than 2027, as additional phase 3 trials continue
US$ 21.67
US$ 24.25
US$ 23.41
US$ 28.56
US$ 25.08
